Patents by Inventor Gregorio Aversa

Gregorio Aversa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal Antibody For Acetylamantadine
    Publication number: 20140287446
    Abstract: A method of producing an antibody comprises immunizing a mammal with an amine-derivative of acetylamantadine, immunizing the mammal with acetylamantadine, and producing the antibody from the mammal. The antibody recognizes acetylamantadine but does not recognize amantadine.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 25, 2014
    Applicant: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Gregorio Aversa, Bram Ramjiawan, Daniel Sitar
  • Therapeutic Binding Molecules
    Publication number: 20110076270
    Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.
    Type: Application
    Filed: June 30, 2010
    Publication date: March 31, 2011
    Inventors: Gregorio AVERSA, Frank KOLBINGER, José M. CARBALLIDO HERRERA, Andreás ASZÓDI, José W. SALDANHA, Bruce M. HALL
  • Therapeutic binding molecules
    Patent number: 7825222
    Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: November 2, 2010
    Assignee: Novartis AG
    Inventors: Gregorio Aversa, Frank Kolbinger, Josè M Carballido Herrera, András Aszódi, José W Saldanha, Bruce M Hall
  • Therapeutic binding molecules
    Publication number: 20060088525
    Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.
    Type: Application
    Filed: December 8, 2005
    Publication date: April 27, 2006
    Inventors: Gregorio Aversa, Frank Kolbinger, Jose Carballido Herrera, Andras Aszodi, Jose Saldanha, Bruce Hall
  • Therapeutic binding molecules
    Publication number: 20050069538
    Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.
    Type: Application
    Filed: September 18, 2003
    Publication date: March 31, 2005
    Inventors: Gregorio Aversa, Frank Kolbinger, Jose Carballido Herrera, Andras Aszodi, Jose Saldanha, Bruce Hall
  • Therapeutic binding molecules
    Publication number: 20040096901
    Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYTH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFYNHGTKYNEKFKG) and said CDR3 having the amino acid seuqnce Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln 8RASQNIGTSIQ), CDR′, having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chmieric or humanised antibody, useful as a pharmaceutical.
    Type: Application
    Filed: January 5, 2004
    Publication date: May 20, 2004
    Inventors: Gregorio Aversa, Frank Kolbinger, Jos?eacute; M Carballido Herrera, Andr?aacute;s Aszdi, Jos?eacute; W Saldanha, Bruce M Hall
  • Methods for modulating SLAM-expressing T cells
    Patent number: 6399065
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: June 4, 2002
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Purified genes encoding mammalian cell surface antigens; proteins and antibodies
    Patent number: 6372899
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: April 16, 2002
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Mammalian cell surface antigens
    Patent number: 5977303
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 2, 1999
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Antibodies to the slam protein expressed on activated T cells
    Patent number: 5576423
    Abstract: Purified genes which encode a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: November 19, 1996
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries